Autologous CD34+ gene-modified cell therapy for sickle cell disease
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Autologous CD34+ gene-modified cell therapy for sickle cell disease, covering 2026-03-04 to 2026-03-04. Get the full timeline:
Most recent: Clinical Trial Update: Efficacy Safety Study of Gene Therapy for Sickle Cell DiseaseSCD Using Autologous CD34+ Cells Transduced ex Vivo, Carrying a Corrected Globin Gene and a Silencing RNA. [Phase 1, Phase 2]